• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Adenosine, 8-chloro-,cyclic 3',5'-[hydrogen (R)-phosphorothioate]: A Comprehensive Overview in Modern Chemical Biology

Adenosine, 8-chloro-,cyclic 3',5'-[hydrogen (R)-phosphorothioate], commonly referred to as Adenosine, 8-chloro-cyclic 3',5'-phosphorothioate, is a sophisticated chemical entity that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, with the CAS number 142754-27-6, represents a novel derivative of adenosine, featuring a chloro substitution at the 8-position and a phosphorothioate group at the 3',5'-positions. The introduction of the (R)-configuration in the phosphorothioate moiety imparts unique biochemical properties, making it a subject of intense study for its potential therapeutic applications.

The structural configuration of Adenosine, 8-chloro-cyclic 3',5'-phosphorothioate is meticulously designed to enhance its biological activity while minimizing off-target effects. The chloro group at the 8-position of adenosine increases the compound's lipophilicity, facilitating better cell membrane penetration. Concurrently, the phosphorothioate linkage introduces a negative charge, which enhances its interaction with biological targets. This dual modification makes it an attractive candidate for developing novel pharmacological agents.

In recent years, there has been a surge in research focused on adenosine receptor agonists due to their broad range of biological functions. Adenosine receptors (A1, A2A, A2B, and A3) are G-protein coupled receptors that play crucial roles in various physiological processes, including cardiovascular regulation, neurotransmission, and immune responses. Among these receptors, A2A adenosine receptor has been extensively studied for its potential in treating neurological disorders, such as Parkinson's disease and Alzheimer's disease. The modified form of adenosine, Adenosine, 8-chloro-cyclic 3',5'-phosphorothioate, has shown promising activity as an A2A receptor agonist.

One of the most compelling aspects of Adenosine, 8-chloro-cyclic 3',5'-phosphorothioate is its enhanced stability compared to native adenosine. The phosphorothioate group replaces one of the oxygen atoms in the phosphate backbone with sulfur, which significantly improves resistance to enzymatic degradation. This stability is critical for drug development, as it ensures prolonged bioavailability and sustained therapeutic effects. Furthermore, the (R)-configuration of the phosphorothioate group has been shown to improve binding affinity and selectivity towards adenosine receptors.

Recent preclinical studies have demonstrated the efficacy of Adenosine, 8-chloro-cyclic 3',5'-phosphorothioate in various models. For instance, studies in murine models of inflammation have shown that this compound effectively reduces inflammatory responses by activating A2A receptors. The anti-inflammatory effects are attributed to its ability to inhibit cytokine production and neutrophil recruitment. Additionally, preclinical trials in models of ischemia-reperfusion injury have highlighted its potential in protecting against tissue damage by modulating adenosine signaling pathways.

The pharmacokinetic profile of Adenosine, 8-chloro-cyclic 3',5'-phosphorothioate is another area of significant interest. Unlike native adenosine, which has a short half-life due to rapid metabolism by ectonucleotidases, this derivative exhibits a longer circulation time. This extended half-life allows for more frequent dosing intervals and potentially reduces the need for high concentrations to achieve therapeutic effects. Pharmacokinetic studies have also revealed that this compound is well-tolerated at therapeutic doses, with minimal side effects observed in animal models.

From a synthetic chemistry perspective, Adenosine, 8-chloro, cyclic 3',5' '-[hydrogen (R)-phosphorothioate] represents a significant advancement in nucleoside chemistry. The synthesis involves multiple steps, including nucleophilic substitution reactions to introduce the chloro group and phosphorothioation to incorporate the sulfur atom into the phosphate backbone. The stereochemistry at the phosphorus atom is critical for biological activity; thus， precise control over reaction conditions is essential to achieve high enantiomeric purity.

The development of Adenosine, 8-chloro, cyclic 3',5' '-[hydrogen (R)-phosphorothioate] also underscores the importance of structure-activity relationship (SAR) studies in drug design. By systematically modifying different parts of the adenosine molecule， researchers can fine-tune its pharmacological properties to optimize efficacy and minimize toxicity. The introduction of the chloro group and phosphorothioate moiety exemplifies how strategic modifications can lead to compounds with enhanced biological activity.

In conclusion, Adenosine, 8-chloro, cyclic 3',5' '-[hydrogen (R)-phosphorothioate] (CAS no: 142754-27-6) is a cutting-edge compound with significant potential in therapeutic applications. Its unique structural features enhance its stability， bioavailability， and binding affinity towards adenosine receptors， making it an attractive candidate for further clinical development。 As research continues to uncover new insights into adenosine signaling pathways， compounds like this are poised to play a pivotal role in treating a wide range of diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)